[Non-European open clinical studies on the efficacy and tolerance of ciclopiroxolamine in dermatomycoses (author's transl)].
A survey is given of twenty published open clinical studies carried out outside Europe. They concern the topical action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic, Hoe 296, Batrafen) in 991 cases of skin disorders, mostly mycoses. 70.7% of the disorders were dermatophytoses, 18.9% candidoses. 6.1% pityriasis versicolor, and 4.2% other skin infections. Four trials were done with 1% Cic cream (o/w-type-emulsion) in 157 dermal disorders and 16 trials with 1% Cic solution (vehicle: polyethylene glycol 400) in 834 cases. Several selected studies are reported in detail, the other are parts of a summarizing survey. After a treatment period which, as a rule, was limited to 3 weeks, the global success rate was 96% (healing and distinct improvement). Any side effects were only seldom recorded.
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy*; D004655:Emulsions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012996:Solutions
D000935:Antifungal Agents; D004655:Emulsions; D011728:Pyridones; D012996:Solutions; D000077768:Ciclopirox
Offene, aussereuropäische Studien zur Wirksamkeit und Verträglichkeit von Ciclopiroxolamin bei Dermatomykosen. Zusammemfassendes Referat.